Abstract 2229P
Background
Selpercatinib, a first-in-class highly selective and potent RET kinase inhibitor with CNS activity, is approved in multiple countries for the treatment of RET-mutant MTC and RET fusion-positive thyroid and lung cancers.
Methods
Updated analysis of selpercatinib in pts with RET fusion-positive thyroid cancer (TC), in LIBRETTO-001 (NCT03157128) was conducted after additional follow up (f/u) of 19 months. Primary endpoint was objective response rate (ORR, RECIST 1.1) by independent review committee (IRC). Secondary endpoints included duration of response (DoR), progression free survival (PFS), and safety.
Results
Efficacy of selpercatinib after RAI (where RAI appropriate) was evaluated in systemic treatment-naïve pts (N=24) and pre-treated pts (N=41) (Table). Naïve and pre-treated pts achieved an ORR of 95.8% and 85.4%, respectively (Table). For pre-treated pts DoR was 26.7 months and PFS was 27.4 months. DoR and PFS data for treatment-naïve pts are still immature approaching and at 2 years, with response ongoing in most pts. At 2 yrs, 95.2% of naïve pts and 57.1% of pre-treated pts remained progression free. In the safety population (N=66), the most common ≥3 grade treatment-emergent adverse events (TEAEs) were: hypertension (15.2%), hyponatraemia (10.6%), diarrhea (7.6%), lymphopenia (7.6%) and increased alanine aminotransferase (6.1%). Two pts (3.0%) discontinued treatment due to TEAEs; 1 pt (1.5%) of these was considered related. Table: 2229P
Treatment naïve (N=24) | Prior treatment (N=41) | |
ORR by IRC, % (95% CI) | 95.8% (78.9, 99.9) | 85.4% (70.8, 94.4) |
Complete response, n (%) | 5 (20.8) | 5 (12.2) |
Partial response, n (%) | 18 (75.0) | 30 (73.2) |
Stable disease, n (%) | 1 (4.2) | 6 (14.6) |
Progressive disease, n (%) | 0 (0.0) | 0 (0.0) |
Not evaluable (NE), n (%) | 0 (0.0) | 0 (0.0) |
PFS by IRC | ||
Median PFS, months (95% CI) | NE (44.2, NE) | 27.4 (14.5, NE) |
Censored, % | 21 (87.5) | 24 (58.5) |
PFS rate at 24 months, % (95% CI) | 95.2 (70.7, 99.3) | 57.1 (38.6, 71.8) |
Median f/u, month | 24.9 | 30.4 |
DoR by IRC | ||
Median DoR, months (95% CI) | NE (42.8, NE) | 26.7 (12.1, NE) |
Censored, % | 21 (91.3) | 20 (57.1) |
DoR rate at 24 months, % (95% CI) | 90.9 (50.8, 98.7) | 50.7 (30.4, 67.8) |
Median f/u, months | 17.8 | 33.9 |
NE; Not estimated.
Conclusions
With longer f/u and additional pts, selpercatinib continues to demonstrate very durable responses in pts with RET-fusion thyroid cancer with or without prior therapy, suggesting use of selpercatinib as first systemic therapy appears to be highly effective in treatment of TC. The safety remained tolerable despite longer duration on treatment.
Clinical trial identification
NCT03157128.
Editorial acknowledgement
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
L.J. Wirth: Financial Interests, Personal, Advisory Board: Bayer, Coherus, Eli Lilly, Eisai, Exelixis; Financial Interests, Personal, Other, Consultant: Curie Therapeutics, Morphic Therapeutics, Tome Biosciences; Financial Interests, Personal, Other, DMSC: PDS Biotherapeutics; Financial Interests, Institutional, Steering Committee Member: Novartis, Eli Lilly. P. Cassier: Financial Interests, Personal, Advisory Board: Merck Serono/EMD, Roche, Amgen, Boehringer ingelheim; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Other, Advisor: OSE Immunotherapeutics; Financial Interests, Institutional, Local PI: AbbVie, Blueprint, Exelixis, GSK, Janssen, Novartis, Roche, Taiho, Loxo/Eli Lilly; Financial Interests, Institutional, Coordinating PI: Amgen; Non-Financial Interests, Institutional, Product Samples: Plexxikon, Novartis, MSD, AstraZeneca, GSK. V. Subbiah: Financial Interests, Institutional, Research Funding: Loxo/Eli Lilly. F.P. Worden: Financial Interests, Personal, Advisory Board: Regeneron, Coherus, Merck, EMD, Serono, Eisai, Eli Lilly, Soligenix, Exelixis; Financial Interests, Personal, Advisory Role: Eisai, EMD, Serono; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Research Funding: Kura Oncology, Merck, Regeneron, Adlai Nortye, Eli Lilly, Loxo. B.J. Solomon: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Merck, Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche/Genentech; Financial Interests, Personal, Advisory Board: Amgen, Roche-Genentech, Eli Lilly, Takeda, Janssen; Financial Interests, Personal, Full or part-time Employment, Employed as a consultant Medical Oncologist at Peter MacCallum Cancer Centre: Peter MacCallum Cancer Centre; Financial Interests, Personal, Member of Board of Directors: Cancer Council of Victoria, Thoracic Oncology Group of Australasia; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Steering Committee Member, Principal Investigator and Steering Committee Chair: Roche/Genentech, Pfizer; Financial Interests, Institutional, Steering Committee Member: Novartis. J. Hadoux: Financial Interests, Personal, Advisory Board: Ipsen, Lilly, Pharma Mar; Financial Interests, Institutional, Invited Speaker: AAA, Pfizer; Financial Interests, Institutional, Advisory Board: Eisai, HRA pharma. D. Weiler: Financial Interests, Personal, Advisory Board, Invited Speaker: Lilly, Roche; Financial Interests, Personal, Advisory Board: MSD, Merck. P. Tomasini: Financial Interests, Personal, Expert Testimony: AZ, Roche, BMS, Takeda, Amgen, JNJ. B.D. Baier: Financial Interests, Personal, Expert Testimony: Eli Lilly. D.S.W. Tan: Financial Interests, Personal, Advisory Board: Amgen, Novartis, Boehringer Ingelheim, C4 Therapeutics, AstraZeneca, GSK, Takeda, Eisai, Guardant, Merck, Pfizer, Roche; Financial Interests, Institutional, Research Grant: AstraZeneca, Amgen, Pfizer, ACM Biolabs; Financial Interests, Personal, Steering Committee Member: Novartis. Y. Lin, T. Bayt: Financial Interests, Personal, Full or part-time Employment: Eli Lilly and Company; Financial Interests, Personal, Stocks or ownership: Eli Lilly and Company. P. Maeda: Financial Interests, Personal, Full or part-time Employment: Eli Lilly and Company; Financial Interests, Personal, Stocks or ownership: Eli Lilly and Company; Financial Interests, Personal, Stocks/Shares: Bayer. A. Drilon: Financial Interests, Personal, Advisory Board: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millennium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, BeiGene, BerGenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem Oncology, MORE Health, AbbVie, 14ner/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros, Novartis, EMD Serono, Melendi, Liberum, Repare RX, Amgen, Janssen, EcoR1, Monte Rosa; Financial Interests, Personal, Other, CME: Medscape, Onclive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, PeerView Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Medscape, Clinical Care Options, AiCME; Financial Interests, Personal, Other, CME, Consulting: Axis; Financial Interests, Personal, Other, Consulting: Nuvalent, Merus, mBrace, EPG Health, Harborside Nexus, Ology, TouchIME, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc; Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical, Remedica Ltd, RV More; Financial Interests, Personal, Stocks/Shares: Treeline Biosciences; Financial Interests, Personal, Royalties: Wolters Kluwer; Financial Interests, Personal, Other, stocks: mBrace; Financial Interests, Institutional, Funding, Research Funding: Pfizer, Exelixis, GSK, Teva, Taiho, PharmaMar; Financial Interests, Personal, Funding, Research: Foundation Medicine; Non-Financial Interests, Member: ASCO, AACR, IASLC; Other, Food/Beverage: Merck, PUMA, Merus; Other: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
2326P - Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy
Presenter: Michele Ghidini
Session: Poster session 16
2327P - The impact of the microenvironment on the intratumoral cellular heterogeneity in colorectal cancer
Presenter: Idan Carmi
Session: Poster session 16
2328P - Alternative molecular mechanisms underpinning breast invasive lobular carcinoma identified by genomics-driven artificial intelligence model
Presenter: Fresia Pareja
Session: Poster session 16
2329P - Evidence for the utility of artificial intelligence and image analysis in Ki-67 quantification in solid tumors
Presenter: Xavier Pichon
Session: Poster session 16
2331P - Interest of next generation sequencing (NGS) for integrated molecular diagnosis of HER2-low breast cancer
Presenter: Jean Louis Merlin
Session: Poster session 16
2332P - Overall survival in breast cancer patients with HER2-low status single- center experience
Presenter: Joanna Huszno
Session: Poster session 16
2333P - Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancers
Presenter: Anna Karlsson
Session: Poster session 16
2334P - Pathologic patterns following different neoadjuvant therapies in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster session 16
2335P - Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma
Presenter: Jianfu Li
Session: Poster session 16